Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients

Phase

Condition

Cutaneous Lupus Erythematosus

Lupus

Musculoskeletal Diseases

Treatment

Mycophenolate Mofetil

Tacrolimus

Hydroxychloroquine

Clinical Study ID

NCT05666336

LYF2022151

Ages 18-75
All Genders
Accepts Healthy Volunteers

Study Summary

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with abnormal activation of B lymphocytes, which may result in many adverse consequences and even death if not treated actively. Telitacicept, approved conditionally in China in March 2021, is a biologic agent targeting B lymphocyte stimulator (BLyS）and a proliferating inducing ligand (APRIL) dually for patients with active SLE patients who have not responded to conventional treatment. The investigators hope to screen predictive biomarkers of efficacy and explore the mechanism of difference in efficacy of Telitacicept with Chinese characteristics by omics.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients with a clinical diagnosis of SLE according to American College ofRheumatology (ACR) classification criteria 1997 and clinically active disease.
Patients with good compliance, will sign the informed consent before the test.
Patients who have received conventional treatment for SLE, and the type and dose oftreatment drugs have been stable for at least 30 days.
Patients who have a positive anti-nuclear antibody test result and SELENA-SLEDAI score ≥8 at screening. If there is a low complement and/or positive anti-dsDNA antibody, theSELENA-SLEDAI score can be defined as ≥ 6 points.

Exclusion

Exclusion Criteria:

Patients with severe lupus nephritis, defined as urinary protein > 6g /24 hours orserum creatinine > 221μmol/L within the last 2 months, or who require hemodialysis.
Patients with SLE-caused or non-SLE-caused central nervous system disease within thelast 2 months.
Patients with severe condition in blood, important organs including heart, liver,gastrointestinal tract and endocrine system which are not related with SLE.
Patients who use prednisone ≥100mg/d over 14 days or receive plasma replacement andsuffer from active infection within the last 1 month.
Patients who received any other targeted agents over the past 12 months.

Study Design

Mycophenolate Mofetil

December 31, 2022

June 30, 2024

Study Description

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with abnormal activation of B lymphocytes, which may result in many adverse consequences and even death if not treated actively. Due to the poor therapeutic efficacy and prominent adverse reactions after long-term use of glucocorticoid combined immunosuppressants, the development of targeted drug use for SLE has become a hot area of research for several years. Telitacicept, approved conditionally in China in March 2021, is a biologic agent targeting B lymphocyte stimulator (BLyS）and a proliferating inducing ligand (APRIL) dually for patients with active SLE patients who have not responded to conventional treatment. As another important part of targeted drug use, the research on biomarkers predictive of drug response is also in full swing in the treatment of SLE. The omics technology has unique advantages in screening biomarkers and exploring the mechanism of drug action. The integrated analysis of multi omics can mutually verify and supplement the screening results of a single omics, so as to more systematically and comprehensively analyze the biological molecular functions and regulatory mechanisms. Therefore, this topic selects serum proteomics combined with metabolomics to screen biomarkers for the prediction of the efficacy of Telitacicept, and to explore the mechanism of the difference in the efficacy of Telitacicept, with a view to providing meaningful reference for the exploration of SLE precise treatment.

Connect with a study center

Department of Rheumatology and Immunology, Xiangya Second Hospital, Central South University
Changsha, Hunan 410000
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.